Asthma

From January 2012 to July 2017, the FDA reportedly received 79 Medical Device Reports (MDRs) pertaining to pneumothorax events, including 16 deaths.

A new study looked at thousands of asthma patients in order to better understand the genetic associations of asthma.

The FDA recently approved the therapy after showing reduction in patients' polyp grade, and reduction in sense of nasal obstruction and congestion.

The trial featured schoolchildren with persistent asthma from an urban region.

The discovery fills a gap in lacking non-drug asthma therapies which health care providers can recommend to patients.

New research shows overweight preschoolers have more frequent asthma symptoms, but inhalers are still effective.

Researchers included smaller city, town, and rural residents for the study, noting they were populations previously excluded from US pollution-based studies.

Breastfeeding is associated with lower odds of developing asthma compared to formula than bottle feeding with expressed breast milk.

The label removal was backed by 4 clinical safety trials involving more than 40,000 patients.

A Lenox Hill Hospital dermatologist outlines the threats surrounding, and ideal therapies for, dermatological conditions brought on by pollution.

The therapy showed up to 51% reduction in the annual exacerbation rate versus placebo.

Two consecutive CHEST studies showed combination therapy's expanding portfolio.

There's a perfect storm brewing that makes telemedicine an inevitability in the management of conditions like asthma and COPD.

After implementing a team-based care approach to COPD, one hospital saved $600 per patient, per year.

As COPD exacerbations continue to plague patients, the AIRWISE trial will examine LAMA/LABA/ICS combinations.

In total, 774 cases of nightmares were reported, with 467 of the cases occurring in patients aged 19 years and younger using montelukast.

The approval marks the first FDA-approved treatment for pulmonary arterial hypertension.

COPD-related deaths increased 11.6% since 1990, and cases increased 44.2% to 174.5 million.

The FDA accepted an abbreviated new drug application for Sandoz ANDA.

CHASE 3 data support FDA approval of Symbicort in children 6 to >12 years.

Already at war over PCSK9, drug giants go to court over another breakthrough drug.

The FDA contraindicated using LABA as monotherapy in adults with asthma.

Meredith McCormack, MD, MHS, talked about managing asthma and COPD in the primary care setting and when it’s time to refer a patient to a specialist at the American College of Physicians Internal Medicine Meeting (ACP 2017) in San Diego, California.

RV/TCL ratios have a stronger association with longer duration asthma.